BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
11/18/2020 2:20:37 PM | Browse: 652 | Download: 1070
 |
Received |
|
2020-03-29 23:42 |
|
Peer-Review Started |
|
2020-03-29 23:53 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2020-06-20 21:56 |
|
Revised |
|
2020-07-29 20:19 |
|
Second Decision |
|
2020-11-04 09:48 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2020-11-05 19:32 |
|
Articles in Press |
|
2020-11-05 19:32 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2020-11-16 13:02 |
|
Publish the Manuscript Online |
|
2020-11-18 14:20 |
| ISSN |
2218-4333 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Review |
| Article Title |
Liquid biopsy in ovarian cancer: Catching the silent killer before it strikes
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Laura Feeney, Ian JG Harley, W Glenn McCluggage, Paul B Mullan and James P Beirne |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
James P Beirne, MBChB, PhD, Doctor, Doctor, Trinity St James Cancer Institute, St. James’ Hospital, James’ Street, Dublin 8, Ireland. j.beirne@qub.ac.uk |
| Key Words |
Epithelial ovarian cancer; Molecular profile; Liquid biopsy; Circulating tumor DNA; Biomarker discovery; Precision medicine |
| Core Tip |
Epithelial ovarian cancer (EOC), particularly high-grade serous carcinoma, is a gynaecological malignancy with a poor survival rate. Currently there is no effective disease-specific biomarker, which could improve detection rates and treatment algorithms, for any of the EOC types - this is an area of unmet clinical need. Circulating tumour DNA (ctDNA) analysis has emerged as a potential blood-based “liquid biopsy” for early detection, diagnosis, staging and prognosis, monitoring response to treatment, monitoring minimal residual disease and relapse and identifying acquired drug resistance mechanisms. However, there are several obstacles to the development of cfDNA-based biomarkers which are discussed further in this in-depth review. |
| Publish Date |
2020-11-18 14:20 |
| Citation |
Feeney L, Harley IJ, McCluggage WG, Mullan PB, Beirne JP. Liquid biopsy in ovarian cancer: Catching the silent killer before it strikes. World J Clin Oncol 2020; 11(11): 868-889 |
| URL |
https://www.wjgnet.com/2218-4333/full/v11/i11/868.htm |
| DOI |
https://dx.doi.org/10.5306/wjco.v11.i11.868 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
